Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Naratriptan.

R Salonen1

  • 1Neurology and Psychiatry Therapeutic Development Group, Glaxo Wellcome, North Carolina 27709, USA.

International Journal of Clinical Practice
|February 29, 2000
PubMed
Summary
This summary is machine-generated.

Naratriptan tablets offer an excellent safety profile for migraine treatment, comparable to placebo. This 5-HT1B/1D agonist provides a sustained action, reducing headache recurrence and serving as a well-tolerated alternative to other pain relievers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical utility gene card for: Meckel syndrome.

European journal of human genetics : EJHG·2011
Same author

Comparison of rizatriptan and sumatriptan.

Headache·2008
Same author

Low maximal oxygen uptake is associated with elevated depressive symptoms in middle-aged men.

European journal of epidemiology·2006
Same author

Increased augmentation of central blood pressure is associated with increases in carotid intima-media thickness in type 2 diabetic patients.

Diabetologia·2005
Same author

C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men.

Diabetologia·2004
Same author

Hepatic lipase C-480T polymorphism modifies the effect of HDL cholesterol on the risk of acute myocardial infarction in men: a prospective population based study.

Journal of medical genetics·2004
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Gastroenterology

Background:

  • Naratriptan is a 5-HT1B/1D agonist developed for acute migraine treatment.
  • It was designed to offer improved tolerability and longer duration of action compared to existing sumatriptan formulations.
  • Migraine treatment often involves a balance between efficacy and patient tolerability.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of naratriptan 2.5 mg tablets in acute migraine.
  • To compare the safety profile of naratriptan with placebo and other migraine treatments.
  • To assess the duration of action and headache recurrence rates associated with naratriptan.

Main Methods:

  • Clinical studies involving over 4000 patients treating more than 15,000 migraine attacks.

Related Experiment Videos

  • Assessment of naratriptan 2.5 mg tablets' tolerability profile against placebo.
  • Evaluation of headache recurrence rates in phase II and III clinical trials.

    • Main Results:

    • Naratriptan 2.5 mg tablets demonstrated an excellent tolerability profile, statistically similar to placebo.
    • The incidence of headache recurrence with naratriptan ranged from 17-28% in clinical trials.
    • Naratriptan offers a sustained duration of action, a key characteristic for migraine management.

    Conclusions:

    • Naratriptan 2.5 mg tablets are a highly tolerable option for acute migraine treatment.
    • Its favorable safety profile and long duration of action make it a suitable alternative to NSAIDs and analgesics.
    • Naratriptan represents a valuable addition to the triptan class for migraineurs seeking effective and safe relief.